The drug cladribine injection, developed by Zhejiang Hisun Pharmaceutical (SHA:600267) unit Hanhui Pharmaceutical, passed the consistency evaluation of China's National Medical Products Administration, the company said in a Wednesday filing on the Shanghai Stock Exchange.
The drug, tested on whether its quality and efficiency were consistent, is used as a treatment for leukemia, according to the Wednesday filing.
Shares of the company fell more than 1% in recent trade.
Price (RMB): ¥7.40, Change: ¥-0.10, Percent Change: -1.33%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments